XML 35 R13.htm IDEA: XBRL DOCUMENT v3.19.1
Income Taxes
12 Months Ended
Dec. 31, 2018
Income Taxes [Abstract]  
Income Taxes

7. Income Taxes



Loss before income taxes consisted of the following components:







 

 

 

 

 

 



 

 

 

 

 

 



 

Year Ended December 31,



 

2018

 

2017

United States

 

$

(7,221,000)

 

$

(6,934,000)

Foreign

 

 

(5,217,000)

 

 

(7,206,000)

Total

 

$

(12,438,000)

 

$

(14,140,000)



The benefit from income taxes consisted of the following components:





 

 

 

 

 

 



 

 

 

 

 

 



 

Year Ended December 31,



 

2018

 

2017

Current:

 

 

 

 

 

 

Federal

 

$

 -

 

$

 -

State

 

 

 -

 

 

 -

Foreign

 

 

 -

 

 

 -



 

 

 -

 

 

 -

Deferred:

 

 

 

 

 

 

 Federal

 

 

-

 

 

-

 State

 

 

-

 

 

-

 Foreign

 

 

(328,000)

 

 

(1,302,000)



 

 

(328,000)

 

 

(1,302,000)

Total

 

$

(328,000)

 

$

(1,302,000)





The Company recorded an income tax benefit of $328,000 and $1.3 million for the year ended December 31, 2018 and 2017, respectively, related to a reduction of the existing deferred tax liability as a result of a  $1.9 million and $5.8 million impairment charge to the Company’s IPR&D assets for the year ended December 31, 2018 and 2017, respectively.





Significant components of the Company’s deferred tax assets and liabilities were as follows:





 

 

 

 

 

 



 

December 31,



 

2018

 

2017

Deferred tax assets:

 

 

 

 

 

 

Net operating loss carryforwards

 

$

44,157,000 

 

$

44,049,000 

Research and development and other tax credits, net

 

 

2,523,000 

 

 

3,109,000 

Stock-based compensation

 

 

272,000 

 

 

188,000 

Other

 

 

196,000 

 

 

165,000 



 

 

47,148,000 

 

 

47,511,000 

Valuation allowance  

 

 

(47,148,000)

 

 

(47,511,000)

Total deferred tax assets

 

 

 -

 

 

 -



 

 

 

 

 

 

Deferred tax liabilities:

 

 

 

 

 

 

  In-process research and development

 

 

(819,000)

 

 

(1,147,000)

Total deferred tax liabilities

 

$

(819,000)

 

$

(1,147,000)



At December 31, 2018, the Company had federal net operating loss (“NOL”) carryforwards of approximately $197.1 million, of which $10.3 million will expire in 2019 unless utilized. Of the remaining carryforwards, $180.5 million will expire in tax years 2020 through 2037. The NOL’s generated in tax years 2018 and forward will carry forward indefinitely, but the deductibility of such federal net operating losses is limited. The Company had state NOL carryforwards of $7.2 million which will begin to expire in 2032. The Company had foreign NOL carryforwards of $10.0 million as of December 31, 2018, $0.9 million of which was generated in 2018. At December 31, 2018, the Company had federal research and development (“R&D”) tax credit carryforwards of approximately $2.5 million, net of a reserve for uncertain tax positions of $1.7 million. The R&D tax credit carryforwards will begin to expire in tax years 2019 through 2031, unless previously utilized. The NOL and tax credit carryforwards may be further subject to the application of Section 382 of the Internal Revenue Code of 1986 (the “Code”) as discussed further below. The Company has provided a valuation allowance to offset the deferred tax assets due to the uncertainty of realizing the benefits of the net deferred tax asset.



The differences between the Company’s effective tax rate and the U.S. federal statutory tax rate were as follows:







 

 

 

 

 

 

 



 

 

 

 

 

 

 



 

 

December 31,



 

 

2018

 

2017



 

 

 

 

 

 

 

U.S. federal statutory income tax rate

 

 

21.0 

%

 

34.0 

%

Adjustments for tax effects of:

 

 

 

 

 

 

 

  Fair value of derivative liabilities

 

 

0.2 

%

 

3.6 

%

  Foreign rate differential

 

 

0.3 

%

 

(4.4)

%

  Stock-based compensation

 

 

(0.3)

%

 

(1.0)

%

  State taxes, net of federal benefit

 

 

0.3 

%

 

(1.7)

%

  Australia refundable R&D tax offset

 

 

(4.6)

%

 

(2.4)

%

  NOL and credit expiration

 

 

(20.3)

%

 

 -

%

  Effect of change in statutory tax rates

 

 

(0.3)

%

 

(184.2)

%

  Change in reserve of uncertain tax positions

 

 

3.2 

%

 

 -

%

  Change in valuation allowance

 

 

3.4 

%

 

170.9 

%

  All other

 

 

(0.1)

%

 

(5.6)

%

Effective income tax rate

 

 

2.8 

%

 

9.2 

%



On December 22, 2017, the U.S. Tax Cuts and Jobs Act (the “Tax Reform Act” or the “Act”)) was signed into law. The Tax Reform Act significantly revised the U.S. corporate income tax regime by, among other things, lowering the U.S. corporate tax rate from 35% to 21% effective January 1, 2018, while also repealing the deduction for domestic production activities, implementing a territorial tax system and imposing a repatriation tax on deemed repatriated earnings of foreign subsidiaries. Shortly after enactment, the SEC staff issued Staff Accounting Bulletin (“SAB”) 118, which provides guidance on accounting for the Tax Reform Act’s impact. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Reform Act enactment date for companies to complete the accounting relating to the Act. To the extent that a company’s accounting for Tax Reform-related income tax effects is incomplete, but the company is able to determine a reasonable estimate, it must record a provisional estimate in its financial statements. As a result of the Tax Reform Act, the Company recorded additional tax expense of $26.0 million during the year ended December 31, 2017, however, this amount was fully offset by a valuation allowance and no net income tax expense or benefit was recorded in the consolidated financial statements. This net tax expense of $0 represents a provisional amount and was the Company’s best estimate. The Company did not record any deemed repatriation tax on unremitted foreign Earnings and Profits (“E&P”) due to the accumulated and projected current deficit in foreign E&P for the year ended December 31, 2017. As of December 31, 2018, the Company has completed its evaluation of the potential impacts of the Tax Reform Act and there was no change to the Company’s previous analysis.



The Company’s past sales and issuances of common and preferred stock have likely resulted in ownership changes as defined by Section 382 of the Code. The Company has not conducted a Section 382 study to date. It is possible that a future analysis may result in the conclusion that a substantial portion, or perhaps substantially all of the Company’s NOL carryforwards and R&D tax credit carryforwards will expire due to the limitations of Sections 382 and 383 of the Code. As a result, the utilization of the carryforwards may be limited and a portion of the carryforwards may expire unused.



The Company has unrecognized tax benefits of approximately $1.7 million related to its federal R&D tax credits as of December 31, 2018. The credits are subject to a valuation allowance and thus, any change to the uncertain tax position reserve would not result in an income tax benefit or expense.



The Company is subject to U.S. federal tax examinations by tax authorities for the years 1998 to 2017 due to the fact that NOL carryforwards exist going back to 1998 that may be utilized on a current or future year tax return.



The Company has a policy of recognizing tax related interest and penalties as additional tax expense when incurred. During the years ended December 31, 2018 and 2017, the Company did not recognize any interest or penalties. The Company does not expect its unrecognized tax benefits will change significantly over the next twelve months.